{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"AURA","limit":50},"count":50,"signals":[{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"prospects. AI presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data. We may use and integrate AI into our business processes both in our own development and implementation of AI and through the adoption of commercially available tools. Development, use, and deployment of these technologies could pose","filed_date":"2026-03-30","accession":"0001193125-26-130401","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130401.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":113,"context":"oduct candidates. Disruptions in financial markets due to unfavorable global economic conditions and inflationary pressures may make equity and debt financings more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. Future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to conti","filed_date":"2026-03-30","accession":"0001193125-26-130401","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130401.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":81,"context":"ember 30, 2025, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2025-11-13","accession":"0001193125-25-278817","full_text":"https://origin.rootz.global/static/filing/0001193125-25-278817.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":81,"context":"June 30, 2025, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2025-08-13","accession":"0001193125-25-179426","full_text":"https://origin.rootz.global/static/filing/0001193125-25-179426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":81,"context":"March 31, 2025, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2025-05-15","accession":"0000950170-25-071907","full_text":"https://origin.rootz.global/static/filing/0000950170-25-071907.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":26,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our i","filed_date":"2025-04-24","accession":"0000950170-25-058062","full_text":"https://origin.rootz.global/static/filing/0000950170-25-058062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":104,"context":"oduct candidates. Disruptions in financial markets due to unfavorable global economic conditions and inflationary pressures may make equity and debt financings more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. To the extent that we raise additional capital through the sale of equity or convertible preferred stock, each investors ownership interests will be dilu","filed_date":"2025-03-24","accession":"0000950170-25-043943","full_text":"https://origin.rootz.global/static/filing/0000950170-25-043943.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":73,"context":"tember 30, 2024, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2024-11-12","accession":"0000950170-24-125428","full_text":"https://origin.rootz.global/static/filing/0000950170-24-125428.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":73,"context":"f June 30, 2024, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2024-08-08","accession":"0000950170-24-093308","full_text":"https://origin.rootz.global/static/filing/0000950170-24-093308.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":20,"context":"Stockholder Matters and (3)Part III, Item 13 Certain Relationships and Related Transactions, and Director Independence of the Original Report, in each case, to update the disclosure for the Companys named executive officers to include J. Jill Hopkins, M.D. and to remove Cadmus C. Rich, M.D. as a named executive officer, and (b)to amend Part III, Item 11 Executive Compensation of the Original Report to correct the calcu","filed_date":"2024-06-14","accession":"0001193125-24-161680","full_text":"https://origin.rootz.global/static/filing/0001193125-24-161680.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":73,"context":"March 31, 2024, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2024-05-09","accession":"0000950170-24-056265","full_text":"https://origin.rootz.global/static/filing/0000950170-24-056265.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":27,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our i","filed_date":"2024-04-25","accession":"0001193125-24-113878","full_text":"https://origin.rootz.global/static/filing/0001193125-24-113878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ministration with SCS MicroinjectorTM. The Phase 2 SC trial, evaluated 22 patients in an open label dose escalation study of bel-sar delivered via SC injection followed by laser light activation. Enrollment is complete in this trial, and data with 12 months of follow up in 90% of patients was presented on November 6, 2023, at the American Academy of Ophthalmology. The results, in patients who receive","filed_date":"2024-03-27","accession":"0000950170-24-036814","full_text":"https://origin.rootz.global/static/filing/0000950170-24-036814.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":97,"context":"oduct candidates. Disruptions in financial markets due to unfavorable global economic conditions and inflationary pressures may make equity and debt financings more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. To the extent that we raise additional capital through the sale of equity or convertible preferred stock, each investors ownership interests will be dilu","filed_date":"2024-03-27","accession":"0000950170-24-036814","full_text":"https://origin.rootz.global/static/filing/0000950170-24-036814.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":23,"context":"e Therapeutics, he was Chief Executive Officer of VelosBio Inc., an oncology company acquired by Merck & Co. for $2.75 billion in 2020. He was also Chief Executive Officer at Acerta Pharma, which was acquired by AstraZeneca for $7 billion. Mr. Johnson has extensive experience leading the development of first-in-class cancer therapies, and has made significant contributions to drugs which ultimately garnered regulatory approva","filed_date":"2024-03-27","accession":"0000950170-24-036814","full_text":"https://origin.rootz.global/static/filing/0000950170-24-036814.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":45,"context":"tember 30, 2023, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2023-11-09","accession":"0000950170-23-062097","full_text":"https://origin.rootz.global/static/filing/0000950170-23-062097.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":43,"context":"f June 30, 2023, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2023-08-09","accession":"0000950170-23-040138","full_text":"https://origin.rootz.global/static/filing/0000950170-23-040138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":45,"context":"tdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2023-05-11","accession":"0000950170-23-021302","full_text":"https://origin.rootz.global/static/filing/0000950170-23-021302.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":23,"context":"Exchange Act of 1934, as amended, the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our i","filed_date":"2023-04-25","accession":"0001193125-23-115288","full_text":"https://origin.rootz.global/static/filing/0001193125-23-115288.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":46,"context":"to the ongoing COVID-19 pandemic or more recently due to unfavorable global economic conditions and inflationary pressures may make equity and debt financings more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. To the extent that we raise additional capital through the sale of equity or convertible preferred stock, each investor&#x2019;s ownership interests will","filed_date":"2023-03-15","accession":"0000950170-23-008166","full_text":"https://origin.rootz.global/static/filing/0000950170-23-008166.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":19,"context":"onduct the businesses in which they are engaged, except where the failure to so qualify or have such power or authority would not reasonably be expected to (i) have, singularly or in the aggregate, a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole, or (ii) impair in any materi","filed_date":"2022-12-05","accession":"0001193125-22-298535","full_text":"https://origin.rootz.global/static/filing/0001193125-22-298535.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"t of current portion |  |  $ |  18,129 |  |  | Laser Purchasing Commitment  On April 5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of &#x20ac;0.2 million each. The first two installments of &#x20ac;0.2 million were paid by the Company in April 2019 and August 2019. Upon receipt of the laser systems, the Company will assess w","filed_date":"2022-11-10","accession":"0000950170-22-024150","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024150.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"tdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2022-11-10","accession":"0000950170-22-024150","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024150.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"tdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2022-08-11","accession":"0000950170-22-016911","full_text":"https://origin.rootz.global/static/filing/0000950170-22-016911.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":41,"context":"tdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2022-05-12","accession":"0000950170-22-009719","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009719.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"Exchange Act of 1934, as amended, the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our i","filed_date":"2022-04-28","accession":"0001193125-22-127614","full_text":"https://origin.rootz.global/static/filing/0001193125-22-127614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"cumented active growth treated at the highest therapeutic regimen had a tumor control rate of 64%.  8 When compared to each patient&#x2019;s rate of tumor growth within the prior two years before enrollment, the growth rate after treatment with AU-011 at any dose demonstrated a statistically significant reduction both when assessing all patients with active growth as well as patients on the maximum t","filed_date":"2022-03-23","accession":"0000950170-22-004425","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004425.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"commercialize product candidates. Disruptions in financial markets in general or more recently due to the COVID-19 pandemic may make equity and debt financings more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. To the extent that we raise additional capital through the sale of equity or convertible preferred stock, each investor&#x2019;s ownership interests will","filed_date":"2022-03-23","accession":"0000950170-22-004425","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004425.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":40,"context":"tdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2021-11-24","accession":"0000950170-21-004908","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":38,"context":"ease clinical trial costs, delay or prevent approval of our product candidates and jeopardize our ability to commence sales and generate revenue.  **If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.** We may not be able to initiate or continue clinical trials for our product candidates","filed_date":"2021-10-25","accession":"0001193125-21-305934","full_text":"https://origin.rootz.global/static/filing/0001193125-21-305934.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"business disruptions, our ability to conduct  **  5  Table of Contents our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2021-10-25","accession":"0001193125-21-305934","full_text":"https://origin.rootz.global/static/filing/0001193125-21-305934.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":32,"context":"ping novel ADCs and bispecific antibodies that was acquired by Merck in 2020 for $2.75 billion. Prior to founding VelosBio Inc. he was the Chief Executive Officer at Acerta Pharma B.V. leading to its acquisition by AstraZeneca plc for $7 billion.  **  3  Table of Contents Risks Associated with our Business** Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an inves","filed_date":"2021-10-25","accession":"0001193125-21-305934","full_text":"https://origin.rootz.global/static/filing/0001193125-21-305934.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":37,"context":"ease clinical trial costs, delay or prevent approval of our product candidates and jeopardize our ability to commence sales and generate revenue.  **If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.** We may not be able to initiate or continue clinical trials for our product candidates","filed_date":"2021-10-08","accession":"0001193125-21-295543","full_text":"https://origin.rootz.global/static/filing/0001193125-21-295543.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"tdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by COVID-19, it is possible that our clinical development timelines cou","filed_date":"2021-10-08","accession":"0001193125-21-295543","full_text":"https://origin.rootz.global/static/filing/0001193125-21-295543.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"ping novel ADCs and bispecific antibodies that was acquired by Merck in 2020 for $2.75 billion. Prior to founding VelosBio Inc. he was the Chief Executive Officer at Acerta Pharma B.V. leading to its acquisition by AstraZeneca plc for $7 billion.  Since our inception, we have raised approximately $218.5 million from leading investors that include among others, Matrix Capital Management, Surveyor Capital (a Citadel company),  **  3","filed_date":"2021-10-08","accession":"0001193125-21-295543","full_text":"https://origin.rootz.global/static/filing/0001193125-21-295543.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"Intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data. We may use and integrate AI into our business processes both in our own development and implementation of AI and through the adoption of commercially available tools. Development, use, and deployment of these technologies could pose","filed_date":"2026-08-11","accession":"0001193125-26-343429","full_text":"https://origin.rootz.global/static/filing/0001193125-26-343429.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":90,"context":"June 30, 2026, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Fac","filed_date":"2026-08-11","accession":"0001193125-26-343429","full_text":"https://origin.rootz.global/static/filing/0001193125-26-343429.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"om August 2017 to September 2024, where he launched the companys lead asset and brought its potential blockbuster in Wet Age-Related Macular Degeneration from pre-clinical development into active enrollment in Phase 3. Prior to Ocular Therapeutix, Inc., beginning in 2009, he served in roles of increasing responsibility at Mundipharma International, including serving as managing director from May 2011","filed_date":"2025-04-24","accession":"0000950170-25-058062","full_text":"https://origin.rootz.global/static/filing/0000950170-25-058062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ology with an initial indication for the treatment of non-muscle invasive bladder cancer, or NMIBC, where we received fast track designation by the FDA&#x2019;s Division of Oncology. We initiated enrollment in a Phase 1 trial and we plan to present initial data from this trial in the second half of 2023.  VDCs are a novel class of drugs with a dual mechanism of action that promotes cancer cell death","filed_date":"2023-03-15","accession":"0000950170-23-008166","full_text":"https://origin.rootz.global/static/filing/0000950170-23-008166.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":", net of current portion |  |  $ |  51 |  |  | Laser Purchasing Commitment  On April 5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of &#x20ac;0.2 million each. The first two installments of &#x20ac;0.2 million were paid by the Company in April 2019 and August 2019. Upon receipt of the laser systems, the Company will assess w","filed_date":"2022-08-11","accession":"0000950170-22-016911","full_text":"https://origin.rootz.global/static/filing/0000950170-22-016911.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"net of current portion |  |  $ |  206 |  |  | Laser Purchasing Commitment  On April 5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of &#x20ac;0.2 million each. The first two installments of &#x20ac;0.2 million were paid by the Company in April 2019 and August 2019. Upon receipt of the laser systems, the Company will assess w","filed_date":"2022-05-12","accession":"0000950170-22-009719","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009719.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":", the Company paid in full its finance lease.  Laser Purchasing Commitment  On April 5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of &#x20ac;0.2 million each. The first two installments of &#x20ac;0.2 million were paid by the Company in April 2019 and August 2019. Upon receipt of the laser systems, the Company will assess w","filed_date":"2021-11-24","accession":"0000950170-21-004908","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"and efficacy of bel-sar as a potential vision-sparing therapy in our ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early choroidal melanoma. We believe enrollment for this Phase 3 trial may be completed in 2026, and we expect to provide top-line data readout for the 15-month primary endpoint in the fourth quarter of 2027. Moreover, we intend to assess the s","filed_date":"2025-11-13","accession":"0001193125-25-278817","full_text":"https://origin.rootz.global/static/filing/0001193125-25-278817.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"EX-99.1 2 aura-ex99_1.htm EX-99.1 Exhibit 99.1 Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights  Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar&#x2019;s Potential to Convert &#x2018;Cold&#x2019; to &#x2018;Hot&#x2019; Tumors,","filed_date":"2025-11-13","accession":"0001193125-25-278810","full_text":"https://origin.rootz.global/static/filing/0001193125-25-278810.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"and efficacy of bel-sar as a potential vision-sparing therapy in our ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early choroidal melanoma. We believe enrollment for this Phase 3 trial may be completed as early as the end of 2025. Moreover, we intend to assess the safety and efficacy of bel-sar in treating a range of other solid tumors, beginning with meta","filed_date":"2025-08-13","accession":"0001193125-25-179426","full_text":"https://origin.rootz.global/static/filing/0001193125-25-179426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"n improving treatment outcomes. We have announced positive data from our Phase 1 clinical trial of bel-sar in patients with NMIBC and have initiated a Phase 1b/2 trial in patients with NMIBC with enrollment expected to begin in the second quarter of 2025. We anticipate initial data from this Phase 1b/2 trial in 2025. We received Fast Track Designation from the FDA for bel-sar for the treatment of NMI","filed_date":"2025-03-24","accession":"0000950170-25-043943","full_text":"https://origin.rootz.global/static/filing/0000950170-25-043943.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"s:** 2,791 --- EX-99.1 2 aura-ex99_1.htm EX-99.1 Exhibit 99.1 Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights  Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026  12-month Stability Completed with New Fo","filed_date":"2026-03-30","accession":"0001193125-26-130383","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130383.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ice of our common stock on December29, 2023, the last trading day of 2023, times the number of unvested restricted stock units. | | |  (3) |  The restricted stock units vest in four equal annual installments following January23, 2023. | | |  (4) |  25% of the shares subject to this stock option vest on the first anniversary of January23, 2023 with the remainder vesting thereafter in 36 equal monthly","filed_date":"2024-06-14","accession":"0001193125-24-161680","full_text":"https://origin.rootz.global/static/filing/0001193125-24-161680.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"d clinical proof of concept, assessed using endpoints in alignment with the feedback from the FDA. We are currently evaluating suprachoroidal, or SC, administration of bel-sar in a Phase 2 trial. Enrollment is complete in the Phase 2 trial, and updated interim data of patients treated with the therapeutic regimen intended to be used in the Phase 3 trial is on track to be presented in the second half","filed_date":"2023-05-11","accession":"0000950170-23-021302","full_text":"https://origin.rootz.global/static/filing/0000950170-23-021302.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AURA","company":"Aura Biosciences, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ial election to our board of directors, each non-employee director will be granted an option to purchase 32,000 shares of our common stock, or Initial Grant. The Initial Grant will vest in equal installments on the first, second, and third anniversaries of the grant date, subject to continued service through the applicable vesting date. Furthermore, on the date of each annual meeting of stockholders,","filed_date":"2022-04-28","accession":"0001193125-22-127614","full_text":"https://origin.rootz.global/static/filing/0001193125-22-127614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"4ceff938de1ff15501908e3ec71fbc4221f9968550b403593bdf59957dc78933","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"d75c3cec7eb74da353d71766e0a570b69c0bc504c6306a61bb57091b2e2526b0","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":4,"hourly_limit":500,"remaining":496,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}